Abstract
The sustained-release system for chemotherapeutic drugs or photosensitizer based on drug-loaded biopolyester nanocarriers can effectively reduce the overall dosage and frequency of administration, thereby mitigating side effects such as immunosuppression and drug resistance caused by prolonged chemotherapy. Compared to polylactic acid (PLA), microorganism-derived polyhydroxyalkanoates (PHAs) exhibits superior biocompatibility and more flexible drug release behavior due to their diverse monomer compositions, slower degradation behavior, and milder acidic degradation products, 3-hydroxybutyric acid (3HB). It explains PHAs are more suitable carriers for chemotherapeutic drugs. In this review, we summarize the current situation of PHA-derived nanocarriers (PHA-NCs) for cancer therapy, including the advantages, preparation methods, and anticancer applications. Furthermore, we also analyzed the current limitations in the application of PHA-NCs for cancer therapy and proposed existing challenges along with strategies for future development. With the rapid advancements in synthetic biology and nanomedicine, we believe that PHA will once again attract significant attention.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
